PART I Overview We are a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. We currently market two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor that was discovered and developed by Ardelyx. NHE3 is an antiporter expressed on the apical surface of the small and large intestines. Tenapanor is a minimally absorbed, first-in-class, oral, small m...
Q2 FY2026 — expected 2026-08-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-19 | 2025-12-31 | 0001437402-26-000013 | EDGAR | 75K words |
| 2025-02-20 | 2024-12-31 | 0001628280-25-006653 | EDGAR | — |
| 2024-02-22 | 2023-12-31 | 0001628280-24-006393 | EDGAR | — |
| 2023-03-02 | 2022-12-31 | 0001628280-23-006041 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0001628280-22-004226 | EDGAR | — |
| 2021-03-08 | 2020-12-31 | 0001558370-21-002500 | EDGAR | — |
| 2020-03-06 | 2019-12-31 | 0001558370-20-002138 | EDGAR | — |
| 2019-03-06 | 2018-12-31 | 0001558370-19-001583 | EDGAR | — |
| 2018-03-14 | 2017-12-31 | 0001558370-18-002056 | EDGAR | — |
| 2017-02-17 | 2016-12-31 | 0001193125-17-047972 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001437402-26-000044 | EDGAR | — |
| 2025-10-30 | 2025-09-30 | 0001437402-25-000018 | EDGAR | 45K words |
| 2025-08-04 | 2025-06-30 | 0001628280-25-037464 | EDGAR | — |
| 2025-05-01 | 2025-03-31 | 0001628280-25-021516 | EDGAR | — |
| 2024-10-31 | 2024-09-30 | 0001628280-24-044551 | EDGAR | — |
| 2024-08-01 | 2024-06-30 | 0001628280-24-034121 | EDGAR | — |
| 2024-05-02 | 2024-03-31 | 0001628280-24-019990 | EDGAR | — |
| 2023-10-31 | 2023-09-30 | 0001628280-23-035597 | EDGAR | — |
| 2023-08-02 | 2023-06-30 | 0001628280-23-026569 | EDGAR | — |
| 2023-05-03 | 2023-03-31 | 0001628280-23-015212 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001628280-22-028180 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001628280-22-021047 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001437402-26-000043 | EDGAR | — |
| 2026-02-19 | 0001437402-26-000012 | EDGAR | 3K words |
| 2026-01-08 | 0001437402-26-000003 | EDGAR | — |
| 2025-12-17 | 0001437402-25-000021 | EDGAR | — |
| 2025-10-30 | 0001437402-25-000016 | EDGAR | — |
| 2025-10-14 | 0001437402-25-000008 | EDGAR | — |
| 2025-08-04 | 0001628280-25-037441 | EDGAR | — |
| 2025-07-03 | 0001628280-25-034132 | EDGAR | — |
| 2025-06-18 | 0001628280-25-032172 | EDGAR | — |
| 2025-05-01 | 0001628280-25-021514 | EDGAR | — |
208 total filings indexed. 176 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001437402 |
| Ticker | ARDX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.ardelyx.com |
| Listed | 2014-06-19 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ARDX (~200 tokens, structured JSON with cryptographic provenance)